Stay updated on Soticlestat in Rare Epilepsies Clinical Trial
Sign up to get notified when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.

Latest updates to the Soticlestat in Rare Epilepsies Clinical Trial page
- Check5 days agoChange DetectedThe study status on the page has been updated to Terminated, with an explanation that termination stemmed from external negative results and not patient safety. This marks the closure of the trial on ClinicalTrials.gov.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page revision was updated to v3.5.4, replacing the previous v3.5.3. This reflects a minor update to the page’s metadata and formatting.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page’s footer revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a minor site release without changing the clinical trial information presented.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check63 days agoChange DetectedThe ENDYMION 1 study (NCT03635073) was terminated due to negative results from related phase 3 studies, and supplementary data were deemed unnecessary. The record now reflects the termination and includes posted results and QC date updates in 2026.SummaryDifference0.1%

- Check70 days agoChange DetectedAdded 'Severe myoclonic epilepsy in infancy' to the Conditions section and removed 'Dravet syndrome'.SummaryDifference0.0%

Stay in the know with updates to Soticlestat in Rare Epilepsies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.